Ron Bentsur, Chairman & CEO, 10% Owner at Nuvectis Pharma, Inc. (NVCT), bought 3,220 shares at $11.09 ($35K) on 2023-10-05, disclosed to the SEC on 2023-10-06.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.95 | 1,820 | $20K | 56.2% |
| 2 | $11.09 | 1,400 | $16K | 43.8% |
| Total | $11.01 avg | 3,220 | $35K | 100% |
| Filing → |
| NVCT | BUY | 2024-12-26 | $21K | — | Filing → |
| NVCT | BUY | 2024-11-18 | $98K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |